

MONTHLY RESPIRATORY PATHOGENS SURVEILLANCE REPORT

 NATIONAL INSTITUTE FOR
COMMUNICABLE DISEASES
Division of the National Health Laboratory Service

SOUTH AFRICA WEEK 26 2021

CONTENTS

Surveillance programme description	2
Comments	3
Systematic Influenza-like illness (ILI) surveillance	4-8
Influenza	
Respiratory syncytial virus	
<i>Bordetella pertussis</i>	
SARS-CoV-2	
Influenza-like illness (ILI) Viral Watch	9-11
Influenza	
Respiratory syncytial virus	
SARS-CoV-2	
National syndromic surveillance for pneumonia	12-16
Influenza	
Respiratory syncytial virus	
<i>Bordetella pertussis</i>	
SARS-CoV-2	
Summary of laboratory confirmed SARS-CoV-2 cases	17-18

CUMULATIVE DATA FROM



HIGHLIGHTS: WEEK 26

- RSV activity remains below seasonal threshold in both influenza-like illness (ILI) and pneumonia surveillance programmes.

- Two new cases of influenza, each from Gauteng Province and North West Province were detected in week 26. From 1 January 2021 to date, 50 influenza cases have been detected from Gauteng, Western Cape, North West, Eastern Cape and KwaZulu-Natal sentinel surveillance sites. The influenza season has not started.

- From 2 March 2020 to 4 July 2021, a total of 1 635 COVID-19 cases were detected from all surveillance programmes. An increase in number of positive samples detected has been noted in pneumonia surveillance in this reporting week compared to previous week, whereas in ILI a slight decline in positive cases was reported. Of the 1190 hospitalised COVID-19 cases reported with available data on outcome, 174 (15%) died.

INFLUENZA, RSV, *BORDETELLA PERTUSSIS* AND SARS-COV-2 SURVEILLANCE REPORT

WEEK 26 2021 | REPORTING PERIOD 4 JANUARY 2021 TO 4 JULY 2021

PROGRAMME DESCRIPTIONS

Programme	Influenza-like illness (ILI)	Viral Watch	National syndromic surveillance for pneumonia
Start year	2012	1984	2009
Provinces*	KZ NW WC** MP***	EC FS GP LP MP NC NW WC	GP KZ MP NW WC
Type of site	Primary health care clinics	General practitioners	Public hospitals
Case definition	<p>ILI: An acute respiratory illness with a temperature ($\geq 38^{\circ}\text{C}$) and cough, & onset ≤ 10 days</p> <p>Suspected pertussis Any person with an acute cough illness lasting ≥ 14 days (or cough illness of any duration for children < 1 year), without a more likely diagnosis AND one or more of the following signs or symptoms:</p> <ul style="list-style-type: none"> • paroxysms of coughing, • or inspiratory “whoop”, • or post-tussive vomiting • or apnoea in children < 1 year; <p>OR</p> <p>Any person in whom a clinician suspects pertussis</p> <p>Suspected SARS-CoV-2 Any person presenting with an acute (≤ 14 days) respiratory tract infection or other clinical illness compatible with COVID-19[§]</p>	<p>ILI: An acute respiratory illness with a temperature ($\geq 38^{\circ}\text{C}$) and cough, & onset ≤ 10 days</p> <p>Suspected SARS-CoV-2 Any person presenting with an acute (≤ 14 days) respiratory tract infection or other clinical illness compatible with COVID-19[§]</p>	<p>SRI: Acute (symptom onset ≤ 10 days) or chronic (symptom onset > 10) lower respiratory tract infection</p> <p>Suspected pertussis Any person with an acute cough illness lasting ≥ 14 days (or cough illness of any duration for children < 1 year), without a more likely diagnosis AND one or more of the following signs or symptoms:</p> <ul style="list-style-type: none"> • paroxysms of coughing, • or inspiratory “whoop”, • or post-tussive vomiting • or apnoea in children < 1 year; <p>OR</p> <p>Any person in whom a clinician suspects pertussis.</p> <p>Suspected SARS-CoV-2 Any person admitted with a physician-diagnosis of suspected COVID-19 and not meeting SRI case definition.</p>
Specimens collected	Oropharyngeal & nasopharyngeal swabs	Throat and/or nasal swabs or Nasopharyngeal swabs	Oropharyngeal & nasopharyngeal swabs
Main pathogens tested****	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2

Epidemic Threshold

Thresholds are calculated using the Moving Epidemic Method (MEM), a sequential analysis using the R Language, available from: <http://CRAN.R-project.org/web/package=mem> designed to calculate the duration, start and end of the annual influenza epidemic. MEM uses the 40th, 90th and 97.5th percentiles established from available years of historical data to calculate thresholds of activity. Thresholds of activity for influenza and RSV are defined as follows: Below seasonal threshold, Low activity, Moderate activity, High activity, Very high activity. For influenza, thresholds from outpatient influenza like illness (Viral Watch Programme) are used as an indicator of disease transmission in the community and thresholds from pneumonia surveillance are used as an indicator of impact of disease.

* EC: Eastern Cape; FS: Free State; GP: Gauteng; KZ: KwaZulu-Natal; LP: Limpopo; MP: Mpumalanga; NC: Northern Cape; NW: North West; WC: Western Cape

**Started in 2019

***Started in November 2020

****INF: influenza virus; RSV: respiratory syncytial virus; BP: *Bordetella pertussis*; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

[§]Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhoea)

COMMENTS

Influenza

The influenza 2021 season has not started. Since the first influenza positive case of 2021 was detected in pneumonia surveillance in week 9 of 2021 (week ending on the 07 March 2021), sporadic cases have been reported from week 16 to date. Of the 50 influenza cases detected in surveillance sites in 2021, the majority (40, 80%) were influenza B/Victoria.

ILI programme: In 2021 to date, specimens from 857 patients meeting ILI case definition were received from 4 ILI sites. Influenza was detected in seven (0.8%) patients, of which four (57.1%) were influenza B(Victoria), two (28.6%) were influenza B (lineage inconclusive) and one (14.2%) influenza B (lineage pending results). (Figure 1 and Table 1).

Viral Watch programme: In 2021 to date, specimens were received from 138 patients from Viral Watch sites in five of the 8 provinces participating in surveillance. Influenza was detected in nine (6.5%) patients, of which four (44%) were influenza B (Victoria), four (44%) influenza B (lineage inconclusive) and one (12%) influenza B (pending lineage results). (Figure 5 and Table 4).

Pneumonia surveillance: Since the beginning of 2021, specimens from 2 745 patients with severe respiratory illness (SRI) were received from the 7 sentinel sites. Influenza was detected in 23 (0.8%) patients, of which one (4.3%) was influenza A(H3N2), 21 (91.4%) influenza B (Victoria) and one (4.3%) was influenza B (pending lineage results). (Figure 9 and Table 7).

In addition, influenza was detected in 11 (2%) specimens, all were influenza B (Victoria) from 481 patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

Respiratory syncytial virus

In 2021 to date, RSV transmission has been reported from all surveillance programmes, activity remains below seasonal threshold.

ILI programme: In 2021 to date, 857 specimens were tested and RSV was detected in specimens of 65 (8%) patients.

Viral Watch programme: During the same period, 138 specimens were tested and RSV was detected in specimens of six (4%) patients.

Pneumonia surveillance: Since the beginning of 2021, 2 745 specimens were tested and RSV was detected in specimens of 342 (12%) patients.

In addition, RSV was detected in 20 of 481 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

Bordetella pertussis

There are no *B. pertussis* cases detected in 2021 in all programmes.

ILI programme: From 1 January 2021 to date, combined nasopharyngeal and oropharyngeal specimens were tested from 839 patients and *B. pertussis* was not detected.

Pneumonia surveillance: During the same period, combined nasopharyngeal and oropharyngeal specimens were tested from 2 672 patients and *B. pertussis* was not detected.

In addition, *B. pertussis* was not detected in 479 specimens from patients who met suspected *B. pertussis* case definition but did not meet the pneumonia/ILI surveillance case definition.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)

Testing for SARS-CoV-2 was initiated in all three surveillance programmes in week 10 of 2020 (week starting 2 March 2020).

ILI programme: From March 2020 to date, specimens from 2 168 patients were tested and SARS-CoV-2 was detected in 368 (17%) patients.

Viral Watch programme: From March 2020 to date, specimens were tested from 417 patients and SARS-CoV-2 was detected in 69 (17%) patients.

Pneumonia surveillance: From March 2020 to date, specimens from 6 723 patients with severe respiratory illness (SRI) were tested and SARS-CoV-2 was detected in 1 198 (18%) patients.

In addition, SARS-CoV-2 was detected in 100 of 673 (15%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

INFLUENZA, RSV, BORDETELLA PERTUSSIS AND SARS-COV-2 SURVEILLANCE REPORT

WEEK **26** 2021

REPORTING PERIOD 4 JANUARY 2021 TO **4 JULY 2021**

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 1. Number of positive samples* by influenza subtype and lineage** and detection rate*** by week

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces

**Influenza was detected in 10 (2.5%) of 396 specimens, of which all were influenza B (Victoria), from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

***Only reported for weeks with >10 specimens submitted

Inconclusive: insufficient viral load in sample and unable to characterise further

B lineage pending results: influenza B results for lineage are pending

Table 1. Cumulative number of influenza subtype and lineage** and total number of samples tested by clinic and province

Clinic (Province)	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/ Victoria	B/ Yamagata	B lineage inconclusive	B lineage pending results ***	Total samples
Agincourt (MP)	0	0	0	0	0	0	0	120
Eastridge (WC)	0	0	0	0	0	0	0	144
Edendale Gateway (KZ)	0	0	0	2	0	2	0	98
Jouberton (NW)	0	0	0	2	0	0	1	404
Mitchell's Plain (WC)	0	0	0	0	0	0	0	91
Total:	0	0	0	4	0	2	1	857

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga

Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza was detected in 10 (2.5%) of 396 specimens, of which all were influenza B (Victoria), from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the table.

***influenza B lineage results are pending

INFLUENZA, RSV, *BORDETELLA PERTUSSIS* AND SARS-COV-2 SURVEILLANCE REPORT

WEEK **26** 2021

REPORTING PERIOD 4 JAN 2021 TO **4 JULY 2021**

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 2. Number of samples testing positive for respiratory syncytial virus** by subgroup and detection rate by week

Inconclusive: insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

**RSV was detected from 15 of 396 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 2. Cumulative number of respiratory syncytial virus subgroups** identified and total number of samples tested by clinic and province

Clinic (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Agincourt (MP)	11	7	1	0	0	120
Eastridge (WC)	17	0	1	0	0	144
Edendale Gateway (KZ)	1	6	0	0	0	98
Jouberton (NW)	2	16	0	1	0	404
Mitchell's Plain (WC)	2	0	0	0	0	91
Total	33	29	2	1	0	857

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga

Inconclusive: insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

*RSV results for subgroups are pending

**RSV was detected from 15 of 396 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 3. Number of samples testing positive for respiratory syncytial virus* by province and detection rate by week

**RSV was detected from 15 of 396 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

INFLUENZA, RSV, *BORDETELLA PERTUSSIS* AND SARS-COV-2 SURVEILLANCE REPORT

WEEK **26** 2021

REPORTING PERIOD 4 JAN 2021 TO **4 JULY 2021**

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 4. Number of samples testing positive for *B. pertussis* and detection rate by month

Table 3. Cumulative number of *B. pertussis* identified and total number of samples** tested by province

Clinic (Province)	<i>B. pertussis</i> Positive**	Total samples tested
Agincourt (MP)	0	115
Eastridge (WC)	0	1144
Edendale Gateway (KZ)	0	98
Jouberton (NW)	0	391
Mitchell's Plain (WC)	0	91
Total:	0	839

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga

**395 cases met the suspected pertussis case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the table or the epidemiological curve

INFLUENZA, RSV, *BORDETELLA PERTUSSIS* AND SARS-COV-2 SURVEILLANCE REPORT

WEEK **26** 2021

REPORTING PERIOD 2 MARCH 2020 TO **4 JULY 2021**

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 5. Number of samples testing positive for SARS-CoV-2* by province and detection rate by week

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces

**SARS-CoV-2 was detected in 79 of 526 (15%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 4. Cumulative number of SARS-CoV-2 identified and total number of samples tested by clinic and province

Clinic (Province)	SARS-CoV-2 positive	Total samples tested
Agincourt (MP)	30	150
Eastridge (WC)	47	632
Edendale Gateway (KZ)	39	239
Jouberton (NW)	185	727
Mitchell's Plain (WC)	67	420
Total:	368	2 168

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga (started enrolling on the 10th November 2020)

**SARS-CoV-2 was detected in 79 of 526 (15%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.

INFLUENZA, RSV, BORDETELLA PERTUSSIS AND SARS-COV-2 SURVEILLANCE REPORT

WEEK 26 2021

REPORTING PERIOD 4 JAN 2021 TO 4 JULY 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 6. Number of positive samples* by influenza subtype and lineage and detection rate** by week

*Specimens from patients with Influenza-like illnesses at 90 sentinel sites in 8 provinces

** Only reported for weeks with >10 specimens submitted.

Inconclusive: insufficient viral load in sample and unable to characterise further

Table 5. Cumulative number of influenza subtype and lineage and total number of samples tested by province

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/ Victoria	B/ Yamagata	B lineage inconclusive	B lineage pending results*	Total samples
Eastern Cape	0	0	0	1	0	0	0	1
Free State	0	0	0	0	0	0	0	0
Gauteng	0	0	0	3	0	4	1	121
Limpopo	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0	0	1
North West	0	0	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0	0	0
Western Cape	0	0	0	0	0	0	0	13
Total:	0	0	0	4	0	4	1	138

*Inconclusive: insufficient viral load in sample and unable to characterise further

From 04 January 2021 to date, no patients were tested for influenza at the time of entry into South Africa following travel abroad.

Patients known to have acquired influenza abroad are not included in the table or epidemiological curve.

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 7. Number of samples testing positive for RSV*, and detection rate by week

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Table 6. Cumulative number of RSV positive cases identified and total number of samples tested by province

Clinic (Province)	RSV positive	Total samples tested
Eastern Cape	0	1
Free State	0	0
Gauteng	4	121
Limpopo	0	0
Mpumalanga	0	1
North West	0	2
Northern Cape	0	0
Western Cape	2	13
Total:	6	138

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 8. Number of samples testing positive for SARS-CoV-2*, and detection rate by week

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Table 7. Cumulative number of SARS-CoV-2 identified and total number of samples tested by province

Clinic (Province)	SARS-CoV-2 positive	Total samples tested
Eastern Cape	1	5
Free State	1	14
Gauteng	56	281
Limpopo	0	2
Mpumalanga	1	6
North West	0	2
Northern Cape	0	2
Western Cape	10	105
Total:	69	417

INFLUENZA, RSV, BORDETELLA PERTUSSIS AND SARS-COV-2 SURVEILLANCE REPORT

WEEK 26 2021

REPORTING PERIOD 4 JAN 2021 TO 4 JULY 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 9. Number of positive samples* by influenza subtype and lineage** and detection rate*** by week

*Specimens from patients hospitalised with pneumonia at 7 sentinel sites in 5 provinces

**Influenza B(Victoria) was detected from one of 85 (1.2%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

***Only reported for weeks with >10 specimens submitted

Inconclusive: insufficient viral load in sample and unable to characterise further

B lineage pending results: influenza B results for lineage are pending

Table 8. Cumulative number of identified influenza subtype and lineage** and total number of samples tested by hospital

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/ Victoria	B/ Yamagata	B lineage inconclusive	B lineage pending results ***	Total samples
Edendale (KZ)	0	0	0	7	0	0	0	370
Helen Joseph-Rahima Moosa (GP)	0	0	0	11	0	0	1	772
Klerksdorp-Tshepong (NW)	0	0	0	3	0	0	0	440
Mapulaneng-Matikwana (MP)	0	0	0	0	0	0	0	328
Red Cross (WC)	0	0	0	0	0	0	0	399
Mitchell's Plain (WC)	0	1	0	0	0	0	0	328
Tintswalo (MP)	0	0	0	0	0	0	0	108
Total:	0	1	0	21	0	0	1	2 745

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape

Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza B(Victoria) was detected from one of 85 (1.2%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.

***influenza B lineage results are pending

INFLUENZA, RSV, BORDETELLA PERTUSSIS AND SARS-COV-2 SURVEILLANCE REPORT

WEEK 26 2021

REPORTING PERIOD 4 JAN 2021 TO 4 JULY 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 10. Number of samples testing positive for respiratory syncytial virus* by subgroup and detection rate by week

Inconclusive: Insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

RSV subgroup pending: RSV results for subgroups are pending

*RSV was detected in five of 85 (6%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 9. Cumulative number of respiratory syncytial virus subgroups** identified and total number of samples tested by hospital

Hospital (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Edendale (KZ)	5	25	0	0	3	370
Helen Joseph-Rahima Moosa (GP)	35	42	0	0	0	772
Klerksdorp-Tshepong (NW)	8	41	0	2	1	440
Mapulaneng-Matikwana (MP)	20	7	1	0	0	328
Red Cross (WC)	64	25	1	4	6	399
Mitchell's Plain (WC)	27	4	1	1	6	328
Tintswalo (MP)	10	3	0	0	0	108
Total:	169	147	3	7	16	2 745

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape

Inconclusive: Insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

*RSV results for subgroups are pending

**RSV was detected in five of 85 (6%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 11. Number of samples testing positive for respiratory syncytial virus* by province and detection rate by week

*RSV was detected in five of 85 (6%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 12. Number of samples testing positive for *B. pertussis* and detection rate by month

Table 10: Cumulative number of *B. pertussis* identified and total number of samples** tested by hospital and province

Hospital (Province)	<i>B. pertussis</i> Positive**	Total samples
Edendale (KZ)	0	368
Helen Joseph-Rahima Moosa (GP)	0	756
Klerksdorp-Tshepong (NW)	0	415
Mapulaneng-Matikwana (MP)	0	317
Red Cross (WC)	0	393
Mitchell's Plain (WC)	0	316
Tintswalo (MP)	0	107
Total:	0	2 672

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape

**84 cases met the suspected pertussis case definition but did not meet Pneumonia Surveillance case definition. These are not included in the table and epidemiologic curve.

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 13. Number of samples testing positive for SARS-CoV-2*, and detection rate by week

*Specimens from patients hospitalised with pneumonia at 6 sentinel sites in 5 provinces

**SARS-CoV-2 was detected in 21 of 147 (14%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 11. Cumulative number of identified SARS-CoV-2 and total number of samples tested by hospital

Hospital (Province)	SARS-CoV-2 positive	Total samples tested
Edendale (KZ)	249	1191
Helen Joseph-Rahima Moosa (GP)	346	1611
Klerksdorp-Tshepong (NW)	296	1033
Mapulaneng-Matikwana (MP)	106	630
Red Cross (WC)	43	1355
Mitchell's Plain (WC)	139	795
Tintswalo (MP)	19	108
Total:	1 198	6 723

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape

**SARS-CoV-2 was detected in 21 of 147 (14%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.

SUMMARY OF LABORATORY CONFIRMED SARS-COV-2 CASES

Table 12. Characteristics of laboratory-confirmed cases of COVID-19, enrolled in influenza-like illness (ILI) and pneumonia surveillance programmes, South Africa, 2 March 2020- 04 July 2021

Characteristic	Influenza-like illness (ILI), public-sector, n=368 (%)	Pneumonia, n=1 198 (%)
Age group		
0-9	35/368 (10)	76/1198 (6)
10-19	26/368 (7)	8/1198 (1)
20-39	156/368 (42)	202/1198 (17)
40-59	119/368 (32)	448/1198 (37)
60-79	30/368 (8)	423/1198 (35)
≥80	2/368 (1)	41/1198 (3)
Sex-female	211/368 (57)	723/1198 (60)
Province*		
Gauteng	N/A	346/1198 (29)
KwaZulu-Natal	39/368 (11)	249/1198 (21)
Mpumalanga**	30/368 (8)	125/1198 (10)
North West	185/368 (50)	296/1198 (25)
Western Cape	114/368 (31)	182/1198 (15)
Race		
Black	260/368 (70)	986/1190 (83)
Coloured	98/368 (27)	138/1190 (12)
Asian/Indian	1/368 (<1)	35/1190 (3)
Other	9/368 (2)	31/1190 (2)
Presentation		
Fever	357/368 (97)	623/1190 (52)
Cough	365/368 (99)	1147/1190 (96)
Shortness of breath	122/368 (33)	942/1190 (79)
Chest pain	157/368 (43)	482/1190 (41)
Diarrhoea	40/368 (11)	74/1190 (6)

INFLUENZA, RSV, *BORDETELLA PERTUSSIS* AND SARS-COV-2 SURVEILLANCE REPORT

WEEK **26** 2021

REPORTING PERIOD 2 MARCH 2020 TO **4 JULY 2021**

Characteristic	Influenza-like illness (ILI), public-sector, n=368 (%)	Pneumonia, n=1 198 (%)
Underlying conditions		
Hypertension	12/368 (3)	124/1190 (10)
Cardiac	0/368 (0)	8/1190 (1)
Lung disease	0/368 (0)	2/1190 (<1)
Diabetes	7/368 (2)	248/1190 (21)
Cancer	0/368 (0)	7/1190 (1)
Tuberculosis	2/368 (1)	30/1190 (3)
HIV-infection	57/368 (15)	247/1190 (21)
Other ***	9/368 (2)	84/1190 (7)
Management		
Oxygen therapy	3/368 (1)	859/1190 (72)
ICU admission	N/A	33/1190 (3)
Ventilation	N/A	36/1190 (3)
Outcome***		
Died	0/368 (0)	174/1190 (15)

*ILI surveillance not conducted in Gauteng province

**Mpumalanga (ILI site started enrolling on the 10th November 2020)

***Chronic lung, liver and kidney disease, organ transplant, pregnancy, malnutrition, obesity, tracheostomy, prematurity, seizure, stroke, anaemia, asplenia, burns, Systemic lupus erythematosus, seizures

****Outcome includes patients who are still hospitalised, have been discharged or referred, and those who died

Note: Children may be over-represented amongst hospitalised patients due to the inclusion of a large paediatric hospital in Cape Town.

Of the 174 patients who died, one was in <20 age group, 15 in the 20-39 year age group, 52 in the 40-59 year age group, and 106 were ≥60 years; 107/174 (61%) were female. All except seven were known to have underlying medical conditions.